EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based study

J C Janssen, A W Schurink, C Verhoef, E Oomen-de Hoop, M W J Louwman, D J Grünhagen, A A M van der Veldt

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2025.116202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von J C Janssen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Surgical Oncology and Gastrointestinal Surgery…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleRetrospective StudiesMiddle AgedChemotherapy, AdjuvantAgedNeoplasm StagingNetherlandsAdultPyridonesOximesImidazolesPyrimidinonesAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

Adjuvant therapyAnti-PD1 therapyStage III melanoma

Substanzen

dabrafenibtrametinibPyridonesOximesImidazolesPyrimidinones

Autor:innen und Institutionen

  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands. Electronic address: a.vanderveld…

Zitieren

APA

Janssen, J. C., Schurink, A. W., Verhoef, C., Oomen-de Hoop, E., Louwman, M. W. J., Grünhagen, D. J., & van der Veldt, A. A. M. (2026). 4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116202

Vancouver

Janssen JC, Schurink AW, Verhoef C, Oomen-de Hoop E, Louwman MWJ, Grünhagen DJ, et al. 4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based study. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116202

BibTeX
@article{Janssen2026,
  author = {Janssen, J C and Schurink, A W and Verhoef, C and Oomen-de Hoop, E and Louwman, M W J and Grünhagen, D J and van der Veldt, A A M},
  title = {4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based study},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2025.116202}
}
Kostenlos starten →